Comparative Effectiveness May Be Next Battleground For First Amendment Fight With FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Lawyers suggest new avenue to challenge restrictions on off-label information; also say FDA appears to be doubling down in rejecting observational studies and comparative analyses.